TECH at a glance
Bio-Techne (TECH, SEC CIK 842023) filed its latest 10-K annual report on August 24, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on September 23, 2026 and Form 4 insider filings as recently as September 30, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended June 30, 2026 (FY2026), Bio-Techne (TECH) reported revenue of $1.2 billion (down 0.4% from FY2025) and net income of $181.8 million. Diluted EPS was $1.16.
- As of June 30, 2026, 37 institutional investment managers tracked by SignalX reported holding Bio-Techne (TECH) shares worth $5.7 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $1.2B
- −0.4% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 37 funds
- $5.7B · +2 vs prior quarter
- Latest 8-K
- Sep 23, 2026
- Item 7.01 · Item 5.07
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Jun 30, 2026
Business Overview
- Core business model: Develop, manufacture, and sell life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets globally
- New emphasis on Diagnostics and Spatial Biology segment with Lunaphore acquisition in fiscal 2024 enhancing automated spatial biology solutions
- Strategic move toward integration as Merck KGaA merger announced in June 2026 with $73.00/share cash offer, expected closing late 2026/early 2027
- Employee base steady at ~3,000 globally with 48% female and 22% nonwhite representation; 1,900+ new products introduced in fiscal 2026
- Diagnostics and Spatial Biology segment now ~28% of net revenues, reflecting increased focus and expansion into adjacent diagnostics markets
Risk Factors
- Regulatory risk: U.S. FDA regulation changes on drug pricing and lab developed tests impacting Diagnostics segment demand and profitability
- Macroeconomic threat: 48% sales outside U.S. exposed to tariffs, geopolitical tensions including U.S.-China trade, raising supply/import costs
- Operational risk: Sole or limited source suppliers and complex FDA-regulated manufacturing may cause production delays and capacity constraints
- Competitive risk: Lunaphore spatial biology solutions acquisition targets rapid innovation, but competitive pressure from multinational and start-ups persists
- Financial risk: $200M drawn on $1B revolving credit facility with covenants limiting transactions, increasing vulnerability to economic or interest rate changes
Management Discussion & Analysis
- Revenue $1.215B, flat YoY (FY26 vs. FY25); Protein Sciences up 1% to $874.6M, Diagnostics down 3% to $336.4M
- Operating gross margin 65.8% vs 64.8%, adjusted gross margin 69.6% vs 70.4%; Protein Sciences margin 75.0% vs 75.6%, Diagnostics margin 55.2% vs 57.3%
- Best segment Protein Sciences: sales $874.6M, +1% YoY; worst Diagnostics: sales $336.4M, -3% YoY, impacted by held-for-sale business divestiture
- Cash flow from operations $292.1M; dividends paid $49.9M; share repurchases $41.7M; capex $28.9M; cash & investments $264.7M, up from $162.2M
- Merger agreement signed with Merck KGaA for $73/share cash buyout; merger expected late 2026 or early 2027; execution subject to regulatory and shareholder approvals
AI summary of the TECH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Mar 31, 2026
Management Discussion & Analysis
- Quarterly revenue $311.4M, down 2% YoY from $316.2M
- Gross margin 66.9% vs 67.9% YoY; adjusted gross margin 70.4% vs 71.6%
- Diagnostics and Spatial Biology revenue $85.6M, down 4%; operating margin 12.1% vs 9.4%
- Protein Sciences revenue $226.2M, down 1%; operating margin 44.2% vs 45.6%
- Cash and investments $214.1M vs $162.2M; nine-month operating cash flow $196.7M vs $189.4M
- Fiscal 2026 capital expenditures approximately $7M remaining; gross margins subject to portfolio mix and headwinds include supply-chain challenges, competition, and currency fluctuations
Risk Factors
- No material risk-factor changes during quarter or nine months ended March 31, 2026
- Carried-forward risks remain those disclosed in the June 30, 2025 Form 10-K
- No newly triggered regulatory, legal, compliance, operational, competitive, market, or financial risks identified in this filing
AI summary of the TECH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Item 7.01 contains only standard Regulation FD non-incorporation language
- No substantive business, financial, or investor-impacting disclosure in the provided text
Item 5.07: Submission of Matters to a Vote of Security Holders
- Merger approved by shareholders, clearing a key condition for Merck KGaA’s acquisition of Bio-Techne
- 121.93M votes for versus 1.21M against, with 30,610 abstentions
Item EX-99.1: Item EX-99.1
- Shareholders approved Merck KGaA’s proposed acquisition, removing a key transaction condition
- Hart-Scott-Rodino waiting period expired September 18, 2026, reducing U.S. antitrust execution risk
Item 5.02: Departure/Appointment of Directors or Principal Officers
- References February 11, 2026 Form 8-K for officer appointments and compensation arrangements
- Executive and director ownership changes reported through SEC Forms 3 or 4
Item 8.01: Other Events
- Merck merger remains subject to shareholder approval at September 23, 2026 special meeting
- Shareholder lawsuit seeks to enjoin the vote, alleging proxy omissions; multiple demand letters create execution risk
Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 contains Bio-Techne’s results for quarter and year ended June 30, 2026
- Press release covers financial condition as of June 30, 2026
Item 8.01: Other Events
- Cash dividend announcement by Bio-Techne, signaling a shareholder capital-return action
- Dividend details and record/payment dates contained in Exhibit 99.2
Item EX-99.1: Item EX-99.1
- Q4 revenue $321.2M, up 1% reported and 3% organic, signaling modest underlying demand improvement
- Adjusted EPS $0.52 versus $0.53, while adjusted operating margin expanded to 32.2% from 32.0%
AI summaries of TECH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TECH
Don't miss the next TECH filing
- Alerts as it files. A push when TECH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TECH, by share count.
- Ask anything. An AI agent that reads every TECH filing and answers with sources.
TECH alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| HIGGINS JOHN L | M | Sep 28, 2026 | 15,940 | - |
| HIGGINS JOHN L | F | Sep 28, 2026 | 5,562 | $72.51 |
| HIGGINS JOHN L | M | Sep 28, 2026 | 15,940 | - |
| BAUMGARTNER ROBERT V | F | Sep 22, 2026 | 5,559 | $72.55 |
| BAUMGARTNER ROBERT V | M | Sep 22, 2026 | 15,940 | - |
| BAUMGARTNER ROBERT V | M | Sep 22, 2026 | 15,940 | - |
| Geist William | A | Aug 17, 2026 | 23,985 | - |
| Geist William | A | Aug 17, 2026 | 14,762 | - |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.2B | $1.2B |
| Gross Profit | - | $790.3M | $799.1M |
| Operating Income | - | $102.3M | $251.9M |
| Net Income | - | $73.4M | $181.8M |
| Gross Margin | - | 64.8% | 65.8% |
| Op. Margin | - | 8.4% | 20.7% |
| Net Margin | - | 6.0% | 15.0% |
| Balance Sheet | |||
| Total Assets | $2.7B | $2.6B | $2.6B |
| Equity | - | $1.9B | $2.1B |
| ROE | - | 3.8% | 8.6% |
| Per Share | |||
| EPS | - | $0.46 | $1.16 |
| Cash Flow | |||
| Operating CF | - | $287.6M | $292.1M |
| CapEx | $62.9M | $31.0M | $28.9M |
Source: XBRL data in Bio-Techne (TECH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TECH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 37 | $5.75B |
| Q1 2026 | 35 | $3.76B |
| Q4 2025 | 30 | $3.97B |
| Q3 2025 | 32 | $3.61B |
| Q2 2025 | 31 | $3.86B |
| Q1 2025 | 26 | $2.94B |
| Q4 2024 | 23 | $3.15B |
| Q3 2024 | 19 | $1.79B |
- Goldman Sachs Group+5.40M (+278%)
- FMR LLC (Fidelity)+4.89M (+62%)
- BlackRock+1.76M (+14%)
- Citadel Advisors LLC+922.5K (+2126%)
- JPMorgan Chase & Co+837.7K (+82%)
- T. Rowe Price Group−2.22M (-91%)
- Morgan Stanley−2.16M (-25%)
- Ameriprise Financial−1.66M (-97%)
- BNY Mellon−480.9K (-27%)
- Principal Financial Group−374.4K (-51%)
- Millennium Management+989.0K
- Soros Fund Management+535.4K
- D.E. Shaw & Co+228.5K
- Mangrove Partners−10.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 233 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TECH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 24, 2026 | - | - | - |
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 10-K | Aug 24, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 8-K | Jun 26, 2026 | - | Analysis | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 4 | Jun 4, 2026 | - | - | |
| 4 | May 12, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
TECH SEC filings: frequently asked questions
Which institutions hold TECH stock?
As of June 30, 2026, the largest Bio-Techne (TECH) holders among the 13F filers tracked by SignalX were BlackRock ($990.9 million), FMR LLC (Fidelity) ($904.0 million), Vanguard Capital Management LLC ($721.9 million), Goldman Sachs Group ($518.8 million), Vanguard Portfolio Management LLC ($459.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TECH's revenue in fiscal year 2026?
For the fiscal year ended June 30, 2026 (FY2026), Bio-Techne (TECH) reported revenue of $1.2 billion (down 0.4% from FY2025) and net income of $181.8 million. Diluted EPS was $1.16. The figures come from the XBRL data in the 10-K.
What are the main risks in TECH's latest 10-K?
In the 10-K filed August 24, 2026, Bio-Techne (TECH) flagged: Regulatory risk: U.S. FDA regulation changes on drug pricing and lab developed tests impacting Diagnostics segment demand and profitability. Macroeconomic threat: 48% sales outside U.S. exposed to tariffs, geopolitical tensions including U.S.-China trade, raising supply/import costs. (AI summary of the Risk Factors section.)
What did TECH report in its latest 8-K?
Bio-Techne (TECH) filed an 8-K on September 23, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 5.07 (Submission of Matters to a Vote of Security Holders). Item 7.01 contains only standard Regulation FD non-incorporation language.
What are the latest TECH SEC filings?
Bio-Techne (TECH) filed its latest 10-K annual report on August 24, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on September 23, 2026 and a Form 4 insider filing on September 30, 2026.
What is TECH's SEC CIK number?
Bio-Techne (TECH)'s SEC Central Index Key (CIK) is 842023. EDGAR lists every TECH filing under that number.
Ask anything about TECH
The research agent reads TECH's filings, financials, insider trades and 13F holders, then answers with sources.